Zogenix Inc. (NASDAQ:ZGNX) saw an uptick in trading volume on Monday . 162,803 shares traded hands during mid-day trading, an increase of 19% from the previous session’s volume of 136,625 shares.The stock last traded at $8.58 and had previously closed at $8.62.

Several brokerages have recently weighed in on ZGNX. Brean Capital reaffirmed a “buy” rating and issued a $28.00 target price on shares of Zogenix in a report on Wednesday, May 11th. Zacks Investment Research downgraded shares of Zogenix from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Zogenix presently has a consensus rating of “Hold” and a consensus target price of $22.75.

The firm has a market cap of $215.01 million and a P/E ratio of 5.14. The stock’s 50 day moving average is $8.67 and its 200 day moving average is $9.65.

Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.20. The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $4.90 million. During the same period in the prior year, the firm posted ($1.19) earnings per share. The business’s revenue for the quarter was up 100.0% compared to the same quarter last year. On average, analysts expect that Zogenix Inc. will post ($3.13) EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in ZGNX. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Zogenix by 400.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 78,456 shares of the company’s stock valued at $1,156,000 after buying an additional 62,769 shares in the last quarter. J. Goldman & Co LP boosted its stake in shares of Zogenix by 72.1% in the fourth quarter. J. Goldman & Co LP now owns 149,500 shares of the company’s stock valued at $2,204,000 after buying an additional 62,615 shares in the last quarter. Finally, Pyrrho Capital Management LP boosted its stake in shares of Zogenix by 13.7% in the fourth quarter. Pyrrho Capital Management LP now owns 148,260 shares of the company’s stock valued at $2,185,000 after buying an additional 17,860 shares in the last quarter.

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.